Word

TRINSERRA

Status

Dead

Status Code

606

Status Date

Monday, November 28, 2022

Serial Number

88893369

Mark Type

4000

Filing Date

Wednesday, April 29, 2020

Published for Opposition

Tuesday, August 31, 2021

Abandoned Date

Monday, November 28, 2022

Trademark Owner History

Xentria, Inc. - Owner At Publication

Classifications

5 house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-interleukin-6 (IL-6) receptor monoclonal antibody for the treatment of disease caused by IL-6 production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders

44 providing medical information; providing health information

42 research and development of biologics, biosimilars, and pharmaceuticals; providing information in the field of scientific and medical research related to biologics, biosimilars, and pharmaceuticals

Trademark Events

Nov 28, 2022

Abandonment Notice E-Mailed - No Use Statement Filed

Nov 28, 2022

Abandonment - No Use Statement Filed

Apr 22, 2022

Notice Of Approval Of Extension Request E-Mailed

Apr 20, 2022

Sou Extension 1 Granted

Apr 20, 2022

Sou Extension 1 Filed

Apr 20, 2022

Teas Extension Received

Oct 26, 2021

Noa E-Mailed - Sou Required From Applicant

Aug 31, 2021

Official Gazette Publication Confirmation E-Mailed

Aug 31, 2021

Published For Opposition

Aug 11, 2021

Notification Of Notice Of Publication E-Mailed

Jul 27, 2021

Approved For Pub - Principal Register

Jul 26, 2021

Teas/Email Correspondence Entered

Jul 26, 2021

Correspondence Received In Law Office

Jul 26, 2021

Teas Request For Reconsideration Received

Jan 29, 2021

Notification Of Final Refusal Emailed

Jan 29, 2021

Final Refusal E-Mailed

Jan 29, 2021

Final Refusal Written

Jan 23, 2021

Teas/Email Correspondence Entered

Jan 22, 2021

Correspondence Received In Law Office

Jan 22, 2021

Teas Response To Office Action Received

Jul 23, 2020

Notification Of Non-Final Action E-Mailed

Jul 23, 2020

Non-Final Action E-Mailed

Jul 23, 2020

Non-Final Action Written

Jul 23, 2020

Assigned To Examiner

May 12, 2020

New Application Office Supplied Data Entered In Tram

May 2, 2020

New Application Entered In Tram